Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"
Jump to navigation
Jump to search
(+ISH) |
|||
| Line 38: | Line 38: | ||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag. | Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag. | ||
</gallery> | </gallery> | ||
==Molecular== | |||
*Testing often done with dual-colour break apart FISH probes.<ref name=pmid27535289>{{cite journal |vauthors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E |title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations |journal=Virchows Arch. |volume=469 |issue=5 |pages=489–503 |date=November 2016 |pmid=27535289 |pmc=5082594 |doi=10.1007/s00428-016-2000-3 |url=}}</ref> | |||
==See also== | ==See also== | ||
Revision as of 02:49, 31 December 2019
ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]
General
- ROS1-rearrangements are seen in approximately 1-2% of non-small cell carcinoma.[2]
- Respond to target therapy, e.g. crizotinib.[3]
Microscopic
Features:
- Histology not definitive; however, predictive features are:[4]
Note:
- Most common pattern varies by specimen type:[4]
- Biopsy specimens: solid pattern most common.
- Resection specimens: acinar pattern most common.
Images
NSmCC - low mag.
NSmCC - intermed. mag.
NSmCC - high mag.
NSmCC - very high mag.
NSmCC - TTF-1 - high mag.
NSmCC - napsin A - high mag.
IHC
- ROS1 +ve.
Images
NSmCC - ROS1 - low mag.
NSmCC - ROS1 - intermed. mag.
NSmCC - ROS1 -high mag.
Molecular
- Testing often done with dual-colour break apart FISH probes.[5]
See also
References
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. October 2019. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
- ↑ "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. July 2019. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
- ↑ 4.0 4.1 "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. 2016. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
- ↑ "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. November 2016. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.